BullFrog AI Secures $7.7M in Equity Financing, Regains Nasdaq Equity Compliance, Extends Cash Runway
BFRG sits 42% above its 52-week low of $0.425.
Summary
BullFrog AI raised $7.7 million in equity, significantly boosting its cash and stockholders' equity to regain Nasdaq compliance on one front, though it still faces a bid price delisting threat and ongoing losses.
Key Events · Financing and Capital Events · BFRG
-
Significant Equity Capital Raise
The company raised approximately $1.9 million through its ATM program and $5.8 million through its ELOC facility (with $3.3 million received post-quarter end), totaling $7.7 million in new equity financing.
-
Nasdaq Stockholders' Equity Compliance Regained
BullFrog AI successfully increased its stockholders' equity to $4.89 million, exceeding the $2.5 million Nasdaq minimum, and received notice on April 21, 2026, that it had regained compliance with this listing rule.
-
Extended Cash Runway
The cash balance increased from $2.18 million at December 31, 2025, to $5.08 million at March 31, 2026, with management expecting current cash to fund operations for at least a year, despite an ongoing 'going concern' warning.
-
Ongoing Nasdaq Bid Price Non-Compliance
The company remains non-compliant with Nasdaq's $1.00 minimum bid price requirement, with a deadline of August 10, 2026, to regain compliance. A reverse stock split is being considered as an option.
Analysis · BFRG · Life Sciences
This quarterly report reveals BullFrog AI successfully raised approximately $7.7 million through its At-The-Market (ATM) program and Equity Line of Credit (ELOC) facility in Q1 2026 and early Q2. This substantial capital injection, representing over 67% of the company's market capitalization, was critical in increasing stockholders' equity from $2.14 million to $4.89 million, allowing the company to regain compliance with Nasdaq's minimum stockholders' equity rule. While highly dilutive, this financing has extended the company's cash runway and addressed a significant delisting threat. However, the company still faces non-compliance with Nasdaq's minimum bid price requirement and is considering a reverse stock split. The net loss for the quarter improved, and a new feasibility agreement with a global pharmaceutical company was noted, though it has not yet generated revenue.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BFRG was trading at $0.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.4M. The 52-week trading range was $0.43 to $2.04. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.